SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the year-ago quarter, underscoring the sustained commercial momentum of its SSi Mantra surgical robotic system. The company also posted a 20.0% rise in gross profit to $7.1 million, though gross margin contracted to 50.9% from 59.1%, reflecting investments in scaling operations and geographic expansion.
For the first half of 2026, revenue reached $25.0 million, up 65.6% from $15.1 million in the same period of 2025. Gross profit surged 77.5% to $12.4 million, with first-half gross margin improving to 49.6% from 46.3% a year earlier. These results highlight the company's ability to convert rising demand into top-line growth while maintaining profitability improvements.
The primary driver of this growth is the SSi Mantra platform, a versatile robotic system designed for multi-specialty surgeries. During the second quarter, installations rose 30.4% to 30 systems, bringing the total installed base to 224 across 12 countries. Cumulatively, surgeons have performed 12,272 procedures using SSi Mantra, demonstrating its clinical utility and growing acceptance in diverse healthcare settings.
Beyond system sales, the company is making strides in telesurgery, a capability that allows surgeons to operate remotely. This innovation extends the clinical profile of SSi Mantra and positions the platform as a leader in next-generation surgical care. However, system installations remain the primary commercial growth driver, with the company focusing on expanding its footprint in existing and new markets.
Looking ahead, regulatory milestones in the United States and Europe could serve as significant catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to two of the world's largest healthcare markets, potentially accelerating adoption and revenue growth.
The company's performance is particularly notable given the competitive landscape in surgical robotics, which is dominated by established players. SS Innovations' ability to grow revenue by nearly 40% year-over-year and nearly double its first-half revenue growth rate suggests that its value proposition—combining advanced technology with cost-effective solutions—is resonating with healthcare providers.
However, the decline in gross margin warrants attention, as it may indicate pricing pressures or increased costs associated with scaling production and support infrastructure. Investors will likely monitor whether the company can maintain profitability while pursuing aggressive expansion.
In summary, SS Innovations' record revenue and expanding installed base signal robust demand for its SSi Mantra platform. The upcoming regulatory milestones could further solidify its market position, making the company a notable player in the evolving surgical robotics sector. As the company continues to execute on its growth strategy, its ability to balance expansion with margin management will be crucial for long-term success.
